Benefit-Risk Appraisal of Medicines - Mussen, Filip (Johnson a Johnson Pharmaceuticals, Belgium) a Salek, Sam (Cardiff University, UK) a Walker, Stuart (CMR International Institute for Regulatory Science, UK)

Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation.